Carcinoma, Pancreatic Ductal
"Carcinoma, Pancreatic Ductal" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Carcinoma that arises from the PANCREATIC DUCTS. It accounts for the majority of cancers derived from the PANCREAS.
| Descriptor ID |
D021441
|
| MeSH Number(s) |
C04.557.470.200.025.232.750 C04.557.470.615.132.750 C04.588.274.761.750 C04.588.322.475.750 C06.301.761.750 C06.689.667.625 C19.344.421.750
|
| Concept/Terms |
Carcinoma, Pancreatic Ductal- Carcinoma, Pancreatic Ductal
- Carcinomas, Pancreatic Ductal
- Ductal Carcinoma, Pancreatic
- Ductal Carcinomas, Pancreatic
- Pancreatic Ductal Carcinomas
- Duct-Cell Carcinoma of the Pancreas
- Duct Cell Carcinoma of the Pancreas
- Pancreatic Ductal Carcinoma
- Ductal Carcinoma of the Pancreas
- Pancreatic Duct Cell Carcinoma
- Carcinoma, Ductal, Pancreatic
- Duct-Cell Carcinoma, Pancreas
- Carcinoma, Pancreas Duct-Cell
- Carcinomas, Pancreas Duct-Cell
- Duct Cell Carcinoma, Pancreas
- Duct-Cell Carcinomas, Pancreas
- Pancreas Duct-Cell Carcinoma
- Pancreas Duct-Cell Carcinomas
|
Below are MeSH descriptors whose meaning is more general than "Carcinoma, Pancreatic Ductal".
- Diseases [C]
- Neoplasms [C04]
- Neoplasms by Histologic Type [C04.557]
- Neoplasms, Glandular and Epithelial [C04.557.470]
- Carcinoma [C04.557.470.200]
- Adenocarcinoma [C04.557.470.200.025]
- Carcinoma, Ductal [C04.557.470.200.025.232]
- Carcinoma, Pancreatic Ductal [C04.557.470.200.025.232.750]
- Neoplasms, Ductal, Lobular, and Medullary [C04.557.470.615]
- Carcinoma, Ductal [C04.557.470.615.132]
- Carcinoma, Pancreatic Ductal [C04.557.470.615.132.750]
- Neoplasms by Site [C04.588]
- Digestive System Neoplasms [C04.588.274]
- Pancreatic Neoplasms [C04.588.274.761]
- Carcinoma, Pancreatic Ductal [C04.588.274.761.750]
- Endocrine Gland Neoplasms [C04.588.322]
- Pancreatic Neoplasms [C04.588.322.475]
- Carcinoma, Pancreatic Ductal [C04.588.322.475.750]
- Digestive System Diseases [C06]
- Digestive System Neoplasms [C06.301]
- Pancreatic Neoplasms [C06.301.761]
- Carcinoma, Pancreatic Ductal [C06.301.761.750]
- Pancreatic Diseases [C06.689]
- Pancreatic Neoplasms [C06.689.667]
- Carcinoma, Pancreatic Ductal [C06.689.667.625]
- Endocrine System Diseases [C19]
- Endocrine Gland Neoplasms [C19.344]
- Pancreatic Neoplasms [C19.344.421]
- Carcinoma, Pancreatic Ductal [C19.344.421.750]
Below are MeSH descriptors whose meaning is more specific than "Carcinoma, Pancreatic Ductal".
This graph shows the total number of publications written about "Carcinoma, Pancreatic Ductal" by people in this website by year, and whether "Carcinoma, Pancreatic Ductal" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2001 | 1 | 0 | 1 |
| 2002 | 2 | 1 | 3 |
| 2003 | 6 | 1 | 7 |
| 2004 | 7 | 2 | 9 |
| 2005 | 6 | 3 | 9 |
| 2006 | 7 | 5 | 12 |
| 2007 | 6 | 3 | 9 |
| 2008 | 18 | 4 | 22 |
| 2009 | 14 | 2 | 16 |
| 2010 | 15 | 2 | 17 |
| 2011 | 28 | 4 | 32 |
| 2012 | 28 | 3 | 31 |
| 2013 | 28 | 3 | 31 |
| 2014 | 42 | 2 | 44 |
| 2015 | 33 | 4 | 37 |
| 2016 | 45 | 6 | 51 |
| 2017 | 43 | 7 | 50 |
| 2018 | 36 | 2 | 38 |
| 2019 | 43 | 6 | 49 |
| 2020 | 45 | 4 | 49 |
| 2021 | 50 | 5 | 55 |
| 2022 | 52 | 0 | 52 |
| 2023 | 42 | 1 | 43 |
| 2024 | 42 | 5 | 47 |
To return to the timeline,
click here.
Below are the most recent publications written about "Carcinoma, Pancreatic Ductal" by people in Profiles.
-
Pancreatic Cancer-Associated Fibroblasts: Where Do We Go from Here? Cancer Res. 2024 Nov 04; 84(21):3505-3508.
-
Mechanisms of Resistance to Oncogenic KRAS Inhibition in Pancreatic Cancer. Cancer Discov. 2024 Nov 01; 14(11):2135-2161.
-
A Phase Ib/II Randomized Clinical Trial of Oleclumab with or without Durvalumab plus Chemotherapy in Patients with Metastatic Pancreatic Ductal Adenocarcinoma. Clin Cancer Res. 2024 Oct 15; 30(20):4609-4617.
-
Surgery for Borderline Resectable Pancreatic Ductal Adenocarcinoma: Preoperative Planning, Technical Considerations, and Building a Program. Surg Clin North Am. 2024 Oct; 104(5):1031-1048.
-
Preventive Treatment with a CD73 Small Molecule Inhibitor Enhances Immune Surveillance in K-Ras Mutant Pancreatic Intraepithelial Neoplasia. Cancer Prev Res (Phila). 2024 Oct 01; 17(10):457-470.
-
Total Venous Control and Vein-to-the-Right Superior Mesenteric Artery Approach in Robotic Pancreatoduodenectomy. Ann Surg Oncol. 2024 Dec; 31(13):8721-8722.
-
Hope on the Horizon: A Revolution in KRAS Inhibition Is Creating a New Treatment Paradigm for Patients with Pancreatic Cancer. Cancer Res. 2024 Sep 16; 84(18):2950-2953.
-
Physical Activity Decreases Inflammation and Delays the Development of Obesity-Associated Pancreatic Ductal Adenocarcinoma. Cancer Res. 2024 Sep 16; 84(18):3058-3071.
-
A rigorous multi-laboratory study of known PDAC biomarkers identifies increased sensitivity and specificity over CA19-9 alone. Cancer Lett. 2024 Nov 01; 604:217245.
-
The KRAS mutational spectrum and its clinical implications in pancreatic cancer. Cancer Cell. 2024 Sep 09; 42(9):1494-1496.